Last updated: February 27, 2026
What is NDC 70677-1274?
NDC 70677-1274 is a specific drug identified by the FDA's National Drug Code. This NDC corresponds to Sovaldi (sofosbuvir), an antiviral medication used primarily to treat hepatitis C virus (HCV) infection.
Current Market Position
Indications and Usage
Sovaldi is approved for treating chronic hepatitis C in adults. It is approved for multiple genotypes (mainly 1, 2, 3, 4, 5, and 6), either as part of combination therapy or as monotherapy in certain cases.
Market Size
The hepatitis C treatment market hit a peak in 2015-2017 due to the launch of multiple direct-acting antivirals (DAAs). The global market was valued at approximately USD 11.8 billion in 2016 and experienced a decline afterward due to the availability of generics.
Competition Landscape
Key competitors include:
- Harvoni (ledipasvir/sofosbuvir)
- Epclusa (sofosbuvir/velpatasvir)
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir)
Patents protecting Sovaldi expired or are set to expire in many key markets, increasing generic entry potential.
Patent and Regulatory Status
Gilead Sciences held patents until around 2020-2022. Post-expiration, generic versions entered markets like India, China, and parts of Europe.
Price Trends and Projections
Historical Pricing
- Original list price in the US (2013): USD 84,000 per treatment course
- Negotiated prices with payers: USD 25,000 to USD 50,000 per course, depending on volume and payer agreements
- Generics in India (2019 onward): USD 300- USD 500 per course
Current Pricing
In the U.S., retail treatment course prices still hover around USD 50,000, although payers and PBMs often secure discounts. Globally, pricing varies widely:
| Region |
Approximate Treatment Price (USD) |
Notes |
| US |
50,000 |
List price; discounts common |
| Europe |
30,000 - 45,000 |
Varies by country and reimbursement policies |
| India |
300 - 500 |
Generics dominate, under patent expiries |
| China |
1,500 - 3,000 |
Growing access with local generics |
Future Price Projections
-
2023-2027: The U.S. treatment prices are expected to stabilize near USD 45,000–USD 55,000 per course, subject to payer negotiations and policy changes.
-
Growth of Generics: Entry of generic versions worldwide will further depress prices, potentially reducing treatment costs to USD 200–USD 1,000 in emerging markets within 3 years.
-
Market Share Shift: As patent expiration leads to increased generic competition, branded sales in the U.S. and Europe could decline by 15-20% annually after 2022.
Market Volume Trends
- The global hepatitis C market was approximately USD 4.8 billion in 2021.
- With increased generic availability and expanded screening, volume will grow in low- and middle-income countries, offsetting declining revenue in high-income nations.
Strategic Implications
- Patent Expiry Impact: Gilead’s revenue from Sovaldi will decrease sharply post-2022 due to patent expiry and generic competition.
- Price erosions: Further discounts and rebates are probable to sustain market share amid rising generics.
- Pipeline and Combination Therapies: Gilead’s focus on combination drugs (e.g., Epclusa, Mavyret) may mitigate revenue losses from Sovaldi alone.
Key Takeaways
- The original USD 84,000 treatment price has declined substantially, and future prices will mirror generic market levels.
- Globally, treatment prices could fall below USD 1,000 per course in the next 3 years.
- Revenue will shift from high-income countries toward markets with new generic entrants.
- The market is consolidating, with Gilead losing exclusivity in many regions.
FAQs
1. What is the primary indication of NDC 70677-1274?
Treatment of chronic hepatitis C virus infection in adults.
2. How has the pricing of Sovaldi changed over time?
List prices started at approximately USD 84,000 per course in 2013, reducing to USD 25,000–USD 50,000 in negotiations, and to USD 300–USD 500 in Indian markets post-generic entry.
3. What factors influence future price projections for this drug?
Patent expiry date, generic market entry, regulatory changes, and payer negotiation strategies.
4. What regions will see the most significant price declines?
Emerging markets such as India, China, and Brazil due to generic competition.
5. How might new developments affect the market?
Introduction of new combination therapies, patent litigation outcomes, and policies surrounding drug pricing could further reshape market dynamics.
References
[1] IMS Health. (2017). The Impact of Patent Expirations on Pharmaceutical Markets.
[2] Gilead Sciences. (2022). Hepatitis C Virus Infection Treatment Guidelines.
[3] IQVIA. (2021). Global Trends in Hepatitis C Market.
[4] World Health Organization. (2021). Hepatitis C: Global Disease Burden.
[5] Statista. (2022). Prices for Hepatitis C Medications in Different Markets.
